Eb Group Sp. z o.o.

The trials here

What the 51 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis26 trials
• Crohn's disease18 trials
• Eosinophilic oesophagitis3 trials
• Graves' disease and hyperthyroidism3 trials
• Macular degeneration3 trials
• Diabetic eye disease1 trial
• Spinal muscular atrophy1 trial

Phase

• Phase 227 trials
• Phase 322 trials
• Phase 2/32 trials

Status

• Completed19 trials
• Recruiting16 trials
• Active, not recruiting11 trials
• Not yet recruiting4 trials
• Suspended1 trial

Lead sponsor

• AbbVie7 trials
• Merck Sharp & Dohme LLC4 trials
• Hoffmann-La Roche3 trials
• Abivax S.A.2 trials
• Celgene2 trials
• and 28 more

Running trials

• Not yet recruiting

  A Phase II/III Multicenter, Randomized, Masked, Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of OCUL101, an Anti-VEGF and Anti-Complement C5, Bi-specific Humanized Antibody-Like “trap” in Participants with Neovascular Age-Related Macular Degeneration with or without Geographic Atrophy – STAT Study

  2026-526648-11-00· Phase 2/3· Shenzhen Oculgen Biomedical Technology Co. Ltd.· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Sitala Bio LTD· Source

• Recruiting

  Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis

  NCT07686081· Phase 3· Vanda Pharmaceuticals· Source

• Recruiting

  A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease

  2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.

  NCT07596849· Phase 3· argenx· Source

• Enrolling by invitation

  Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

  NCT07652294· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis

  NCT07470879· Phase 2· Pfizer· Source

• Recruiting

  A Phase 2 Platform Study to Evaluate Therapies for Inflammatory Bowel Disease

  2025-522001-38-00· Phase 2· Mirador Therapeutics Inc.· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT06979336· Phase 2· Genentech, Inc.· Source

• Recruiting

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  NCT07071519· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

  NCT06975722· Phase 2· Sanofi· Source

• Active, not recruiting

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· Phase 3· AbbVie· Source

• Recruiting

  A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

  NCT06962839· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

  NCT06958536· Phase 2· Sanofi· Source

• Recruiting

  A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

  NCT07012395· Phase 2· Spyre Therapeutics, Inc.· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

  NCT06727604· Phase 2· Immunovant Sciences GmbH· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

  NCT06651281· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

  NCT06456593· Phase 2· Abivax S.A.· Source

• Active, not recruiting

  A Study to Investigate the Efficacy and Safety of NSI-8226 in Adults With Eosinophilic Esophagitis

  NCT06598462· Phase 2· Uniquity One (UNI)· Source

• Active, not recruiting

  Phase IIa Study Evaluating AZD7798 in Crohn's Disease

  NCT06450197· Phase 2· AstraZeneca· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05668013· Phase 2· Teva Branded Pharmaceutical Products R&D LLC· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

  NCT03398135· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease

  NCT03105102· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· Phase 3· AbbVie· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Ulcerative colitis9 recruiting
• Crohn's disease6 recruiting
• Graves' disease and hyperthyroidism3 recruiting
• Macular degeneration2 recruiting
• Diabetic eye disease1 recruiting

Closed trials

• Completed

  A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.

  2023-507705-34-00· Phase 3· Alvotech Swiss AG· Source

• Completed

  Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitis

  2023-508679-34-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.

  NCT06176560· Phase 3· Faes Farma S.A.· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants with Moderate to Severe Ulcerative Colitis

  2023-506655-19-00· Phase 2· Genentech Inc.· Source

• Completed

  A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

  NCT05774184· Phase 2· Celldex Therapeutics· Source

• Completed

  Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Oral Ozanimod in Pediatric Participants with Moderately to Severely Active Crohn's Disease with an Inadequate Response to Conventional Therapy

  2023-508777-91-00· Phase 2/3· Celgene International II S.a.r.l.· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Completed

  A Study to Test the Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease

  NCT05499130· Phase 2· Teva Branded Pharmaceutical Products R&D, Inc.· Source

• Completed

  Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

  NCT04991935· Phase 3· Celgene· Source

• Completed

  VTX002 versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

  2023-509233-39-00· Phase 2· Oppilan Pharma Limited· Source

• Completed

  A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration

  NCT04757610· Phase 3· Opthea Limited· Source

• Completed

  A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

  NCT05013905· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Completed

  A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

  NCT04996797· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Completed

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· Phase 3· Celgene International II SARL· Source

• Completed

  Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease

  2023-510426-33-00· Phase 3· Celgene International II S.a.r.l.· Source

• Active, not recruiting

  A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

  NCT03345823· Phase 3· AbbVie· Source

• Completed

  A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy

  NCT03032172· Phase 2· Hoffmann-La Roche· Source

• Completed

  An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

  NCT02531126· Phase 3· Celgene· Source

• Completed

  Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

  NCT02632175· Phase 3· AbbVie· Source